KR880701072A - 혈장을 함유하지 않는 수혈가능한 혈소판 저장 합성 매질 - Google Patents

혈장을 함유하지 않는 수혈가능한 혈소판 저장 합성 매질

Info

Publication number
KR880701072A
KR880701072A KR1019870701061A KR870701061A KR880701072A KR 880701072 A KR880701072 A KR 880701072A KR 1019870701061 A KR1019870701061 A KR 1019870701061A KR 870701061 A KR870701061 A KR 870701061A KR 880701072 A KR880701072 A KR 880701072A
Authority
KR
South Korea
Prior art keywords
storage medium
sodium
platelet storage
electrolyte solution
chloride
Prior art date
Application number
KR1019870701061A
Other languages
English (en)
Other versions
KR920005684B1 (ko
Inventor
홀름 스타인
Original Assignee
원본미기재
아메리칸 레드 크로스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 아메리칸 레드 크로스 filed Critical 원본미기재
Publication of KR880701072A publication Critical patent/KR880701072A/ko
Application granted granted Critical
Publication of KR920005684B1 publication Critical patent/KR920005684B1/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/80—Multi-analyte reference solutions containing cholesterol, glucose and the like
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

내용 없음

Description

혈장을 함유하지 않는 수혈가능한 혈소판 저장 합성 매질
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 전해질 용액 1ℓ에 데그크로즈 약 3.0내지 약 7.5g ; 시트르산나트륨 약 3.0내지 약 6.0g ; 및 중탄산나트륨 약 2.0내지 약 4.2g을 함유하는 생리학적으로 허용되는 수성 전해질 용액으로 이루어지고, 등장성이며 pH 범위가 약 6.8내지 약 7.4이고, 약 22℃ 이상의 온도에서 약 10일 이상동안 혈소판을 보존할 수 있음을 특징으로 하는 무균성 혈장-비함유 저장매질.
  2. 제1항에 있어서, 추가로 시트르산을 함유하며, 혈소판 저장매질 1ℓ당 시트르산은 약 0.51g의 농도, 덱스트로즈는 약 7.035g의 농도, 시트르산나트륨은 약 4.471g의 농도, 및 중탄산나트륨은 약 3.0g의 농도로 존재함을 특징으로 하는 혈소판 저장매질.
  3. 전해질 용액 1ℓ에 덱스트로즈 약 3.0내지 약 7.5g; 시트르산나트륨 약 3.0내지 약 6.0g; 시트르산 약 0.4내지 약 0.6g; 및 중탄산나트륨 약 2.0내지 약 4.2g을 함유하는 생리학적으로 허용되는 수성 전해질 용액으로 필수적으로 구성되며, 등장성이고 pH범위가 약 6.8내지 약 7.4이고, 약 22℃ 이상의 온도에서 약 14일 이상 동안 혈소판을 보존하는 무균성 혈장-비함유 저장 매질.
  4. 제3항에 있어서, 1ℓ중에 덱스트로즈는 약 7.035g의 농도, 시트르산나트륨은 약 4.471g의 농도, 시트르산은 약 0.51g의 농도, 중탄산나트륨은 약 3.0g의 농도로 존재하는 혈소판 저장 매질.
  5. 제1항 또는 제3항에 있어서, 전해질 용액 1ℓ에 염화나트륨 약 6.4내지 약 7.6g ; 염화칼륨 약 0.2내지 약 0.4g ; 염화칼륨 약 0.1 내지 약 0.4g ; 황산 마그네슘 약 0.2내지 약 0.4g ; 및 일염기성 인산나트륨 약 0.1내지 약 0.6g을 포함하는 전해질이 함유되어 있는 혈소판 저장 매질.
  6. 제1항 또는 제3항에 있어서, 전해질 용액 1ℓ에 염화나트륨 약 6.45g ; 염화칼륨 약 0.375g ; 염화칼슘 약 0.248g ; 황산마그네슘 약 0.2g ; 및 일염기성 인산나트륨 약 0.355g을 포함하는 전해질이 함유되어 있는 혈소판 저장 매질.
  7. 제6항에 있어서, 추가로 인체 혈액의 혈소판 농축물을 함유하며, 인체혈액과 등장성인 혈소판 저장 매질.
  8. 전해질 용액 1ℓ에 덱스트로즈 약 3.0내지 약 7.5g ; 시트르산나트륨 약 3.0내지 약 6.0g ; 및 중탄산나트륨 약 2.0내지 약 4.2g을 함유하는 생리학적으로 허용되는 수성 전해질 용액을 제조하고, 등장성이며, pH범위가 약 6.8내지 7.4인 혈소판 저장 매질에 혈소판을 현탁시킴으로써 혈소판의 실제적인 농도가 약 22℃ 이상의 온도에서 약 14일 이상 동안 생존가능한 상태로 유지되도록 함을 특징으로 하여, 무균성 혈장-비함유 혈소판 저장 매질중에서 혈소판을 보존하는 방법.
  9. 제8항에 있어서, 상기 언급한 제조단계에서 시트르산을 함유하는 혈소판 저장매질이 생성되며, 혈소판 저장매질 1ℓ에는 시트르산 약 0.51g ; 덱스트로즈 약 7.035g ; 시트르산나트륨 약 4.471g ; 및 중탄산나트륨 약 3.0g이 함유되는 방법.
  10. 제9항에 있어서, 상기 언급한 제조단계에서 염화나트륨 약 6.4내지 약 7.6g ; 염화칼륨 약 0.2내지 약 0.4g ; 염화칼슘 약 0.1내지 약 0.4g ; 황산마그네슘 약 0.2내지 약 0.4g ; 및 일염기성 인산나트륨 약 0.1내지 약 0.6g을 포함하는 전해질이 함유된 혈소판 저장매질 1ℓ가 생성되는 방법.
  11. 제9항에 있어서, 상기 언급한 제조 단계에서 염화나트륨 약 6.45g ; 염화칼륨 약 0.375g ; 염화칼슘 약 0.248g ; 황산마그네슘 약 0.2g ; 및 임염기성 인산나트륨 약 0.355g을 포함하는 전해질이 함유된 혈소판 저장매질 1ℓ가 생성되는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870701061A 1986-03-19 1987-01-20 혈장을 함유하지 않는 수혈가능한 혈소판 저장 합성매질 KR920005684B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US06/841,435 US4695460A (en) 1986-03-19 1986-03-19 Synthetic, plasma-free, transfusible platelet storage medium
US841,435 1986-03-19
US841435 1986-03-19
PCT/US1987/000062 WO1987005468A1 (en) 1986-03-19 1987-01-20 Synthetic, plasma-free, transfusible platelet storage medium

Publications (2)

Publication Number Publication Date
KR880701072A true KR880701072A (ko) 1988-07-25
KR920005684B1 KR920005684B1 (ko) 1992-07-13

Family

ID=25284882

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870701061A KR920005684B1 (ko) 1986-03-19 1987-01-20 혈장을 함유하지 않는 수혈가능한 혈소판 저장 합성매질

Country Status (16)

Country Link
US (1) US4695460A (ko)
EP (2) EP0266363A1 (ko)
JP (1) JPH07121841B2 (ko)
KR (1) KR920005684B1 (ko)
AT (1) ATE51999T1 (ko)
AU (1) AU589086B2 (ko)
BR (1) BR8706207A (ko)
CA (1) CA1299110C (ko)
DE (1) DE3762299D1 (ko)
FI (1) FI86253C (ko)
IE (1) IE60063B1 (ko)
IL (1) IL81708A0 (ko)
NZ (1) NZ219399A (ko)
WO (1) WO1987005468A1 (ko)
ZA (1) ZA871365B (ko)
ZW (1) ZW4387A1 (ko)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5176921A (en) * 1983-05-02 1993-01-05 Diamond Scientific Co. Method of blood component decontamination by glucose addition
US4828976A (en) * 1983-12-29 1989-05-09 Thomas Jefferson University Glucose free media for storing blood platelets
US5248506A (en) * 1986-03-19 1993-09-28 American National Red Cross Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets
US4961928A (en) * 1986-03-19 1990-10-09 American Red Cross Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets
US4944918A (en) * 1988-01-15 1990-07-31 Becton, Dickinson And Company Sterilization of blood component separation devices
US4994367A (en) * 1988-10-07 1991-02-19 East Carolina University Extended shelf life platelet preparations and process for preparing the same
US5573940A (en) * 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US4925665A (en) * 1989-06-22 1990-05-15 Thomas Jefferson University Glucose free primary anticoagulant for blood containing citrate ions
US5236716A (en) * 1990-02-12 1993-08-17 Miles Inc. Platelets concentrate with low white blood cells content
US5089146A (en) 1990-02-12 1992-02-18 Miles Inc. Pre-storage filtration of platelets
CA2071833C (en) * 1990-11-07 1998-11-03 Jean-Marc Payrat Red blood cell storage solution
US5569579A (en) * 1991-04-01 1996-10-29 Thomas Jefferson University Synthetic-based platelet storage media
US5376524A (en) * 1991-04-01 1994-12-27 Thomas Jefferson University Platelet storage medium containing acetate and phosphate
US5256571A (en) * 1991-05-01 1993-10-26 Cytyc Corporation Cell preservative solution
US5344752A (en) * 1991-10-30 1994-09-06 Thomas Jefferson University Plasma-based platelet concentrate preparations
US5234808A (en) * 1991-10-30 1993-08-10 Thomas Jefferson University Acetate addition to platelets stored in plasma
US5474891A (en) * 1991-10-30 1995-12-12 Thomas Jefferson University Plasma-based platelet concentrate preparations with additive
US5328821A (en) * 1991-12-12 1994-07-12 Robyn Fisher Cold and cryo-preservation methods for human tissue slices
US5459030A (en) * 1992-03-02 1995-10-17 Steritech, Inc. Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US5618662A (en) * 1992-03-02 1997-04-08 Cerus Corporation Intravenous administration of psoralen
WO1996014740A1 (en) * 1992-03-02 1996-05-23 Cerus Corporation Synthetic media for blood components
US5709991A (en) * 1992-03-02 1998-01-20 Cerus Corporation Proralen inactivation of microorganisms and psoralen removal
EP0642301B1 (en) * 1992-05-29 2003-03-12 The University Of North Carolina At Chapel Hill Pharmaceutically acceptable fixed-dried human blood platelets
US5494590A (en) * 1992-06-11 1996-02-27 Becton Dickinson Method of using anticoagulant solution in blood separation
CA2101610A1 (en) * 1992-08-07 1994-02-08 William D. Prevatt Production of bacillus entomotoxins in methylotrophic yeast
CA2141803C (en) * 1992-08-07 2003-06-17 Lily Lin Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen
DE4230513C1 (de) * 1992-09-11 1994-03-31 Fresenius Ag Vorrichtung zur Entfernung von Aluminiumionen aus Blut und Lösung zur Verwendung in der Vorrichtung
WO1996018292A1 (en) 1994-12-16 1996-06-20 Baxter International Inc. Controlling donor blood characteristics
DE19634313A1 (de) * 1996-08-24 1998-02-26 Behringwerke Ag Methode zur Stabilisierung von Plättchen
US5906744A (en) * 1997-04-30 1999-05-25 Becton Dickinson And Company Tube for preparing a plasma specimen for diagnostic assays and method of making thereof
US7166568B1 (en) 1998-02-09 2007-01-23 Oklahoma Medical Research Foundation Compositions and methods to inhibit formation of the C5b-9 complex of complement
US6277337B1 (en) 1998-07-21 2001-08-21 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US6258577B1 (en) 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US6413713B1 (en) 1998-10-30 2002-07-02 Hyperbaric Systems Method for preserving blood platelets
JP2002538185A (ja) * 1999-03-11 2002-11-12 ハイパーベイリック システムズ 血小板を保存するための組成物及び方法
US6398972B1 (en) * 1999-04-12 2002-06-04 Harvest Technologies Corporation Method for producing platelet rich plasma and/or platelet concentrate
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US6268120B1 (en) 1999-10-19 2001-07-31 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US6770478B2 (en) 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
AU2001234978A1 (en) * 2000-02-10 2001-08-20 The Regents Of The University Of California Therapeutic platelets and methods
US7985588B2 (en) 2000-06-02 2011-07-26 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US7648699B2 (en) 2000-06-02 2010-01-19 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
TW590780B (en) 2000-06-02 2004-06-11 Gambro Inc Additive solutions containing riboflavin
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US6548241B1 (en) * 2000-11-28 2003-04-15 Gambro, Inc. Storage solution containing photosensitizer for inactivation of biological contaminants
US7183045B2 (en) * 2002-04-24 2007-02-27 Gambro Inc. Removal of adenine during a pathogen reduction process in whole blood or red blood cell by dilution
CA2499463A1 (en) * 2002-11-08 2004-05-27 The Brigham And Women's Hospital, Inc. Compositions and methods for prolonging survival of platelets
AU2004232350A1 (en) * 2003-04-23 2004-11-04 Human Biosystems Improved methods and solutions for storing donor organs
WO2004112477A1 (en) * 2003-06-20 2004-12-29 Pall Corporation Processing of platelet-containing biological fluids
US8835104B2 (en) 2007-12-20 2014-09-16 Fenwal, Inc. Medium and methods for the storage of platelets
WO2010039994A2 (en) * 2008-10-01 2010-04-08 Caridianbct, Inc. Platelet additive solution for leukoreducing white blood cells in apheresed platelets
EP2211046B1 (en) * 2008-12-29 2011-03-02 C.R.F. Società Consortile per Azioni Fuel injection system with high repeatability and stability of operation for an internal-combustion engine
US8980542B2 (en) 2010-02-16 2015-03-17 Viacell, Llc Arginine-containing compositions and methods for treating red blood cells
US20110229871A1 (en) 2010-02-16 2011-09-22 Ericson Daniel G Nucleoside-containing compositions and methods for treating red blood cells
AU2012228972A1 (en) 2011-03-16 2013-10-24 Dynasil Biomedical Corporation Methods and materials for prolonging useful storage of red blood cell preparations and platelet preparations
WO2012139017A1 (en) * 2011-04-07 2012-10-11 Fenwal, Inc. Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates
US9788539B2 (en) 2011-05-17 2017-10-17 Velico Medical, Inc. Platelet protection solution having beta-galactosidase and sialidase inhibitors
EP2903430A1 (en) 2012-10-05 2015-08-12 Velico Medical, Inc. Platelet additive solution having a beta-galactosidase inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2786014A (en) * 1952-09-10 1957-03-19 James L Tullis Platelet preservation
US3629071A (en) * 1970-02-10 1971-12-21 Upjohn Co Storage-stable hemostatic transfusion suspensions of blood platelets, glucose, magnesium chloride and certain prostaglandins
GB2034463B (en) * 1978-11-11 1983-03-30 Ryan W Plaetelet reference control
US4390619A (en) * 1981-09-28 1983-06-28 James Clifford Haight Leukocyte or platelet storage using ion-exchange resins
US4489162A (en) * 1981-12-21 1984-12-18 American Hospital Supply Corporation Fresh blood (unfixed) hematology control
CA1216518A (en) * 1982-11-01 1987-01-13 Gail A. Rock Plasma-free medium for platelet storage
CA1244774A (en) * 1983-11-09 1988-11-15 Thomas Jefferson University Medium for storing blood platelets

Also Published As

Publication number Publication date
EP0266363A1 (en) 1988-05-11
EP0237863A1 (en) 1987-09-23
ATE51999T1 (de) 1990-05-15
US4695460A (en) 1987-09-22
FI875063A0 (fi) 1987-11-16
NZ219399A (en) 1989-05-29
FI875063A (fi) 1987-11-16
AU589086B2 (en) 1989-09-28
WO1987005468A1 (en) 1987-09-24
BR8706207A (pt) 1988-02-23
DE3762299D1 (de) 1990-05-23
FI86253C (fi) 1992-08-10
IE870608L (en) 1987-09-19
AU6892187A (en) 1987-10-09
ZA871365B (en) 1987-09-30
KR920005684B1 (ko) 1992-07-13
CA1299110C (en) 1992-04-21
FI86253B (fi) 1992-04-30
EP0237863B1 (en) 1990-04-18
ZW4387A1 (en) 1987-06-03
IL81708A0 (en) 1987-09-16
JPS63503381A (ja) 1988-12-08
JPH07121841B2 (ja) 1995-12-25
IE60063B1 (en) 1994-05-18

Similar Documents

Publication Publication Date Title
KR880701072A (ko) 혈장을 함유하지 않는 수혈가능한 혈소판 저장 합성 매질
KR890009409A (ko) 기관 보존 및 저장에 적당한 조성물 및 기관 보조 방법
ATE86862T1 (de) Glukosefreie medien zur lagerung von blutplaettchen.
US4704352A (en) L-ascorbate-2-phosphate salts in blood cell storage
DE3886006T2 (de) Synthetisches, plasmafreies, übertragbares Konservierungsmittel für rote Blutkörperchen.
DK305785A (da) Fremgangsmaade og medium til opbevaring af blodplader
DE3584010D1 (de) Verlaengertes lagern roter blutzellen.
Friedl et al. Role of oxygen radicals in tourniquet-related ischemia-reperfusion injury of human patients
AU563215B2 (en) Sterilizable storage solution for red blood cells
JPS6363616A (ja) 赤血球濃厚液の保存剤及び保存方法
ES8405350A1 (es) Un procedimiento para preparacion de isomeros trans de bis-(perfuoralquil)-1,2-etenos.
DE3686584D1 (de) Stabilisierung von leukozyten.
FI844436A0 (fi) Foerfarande foer framstaellning av ett foedoaemne som har avsaltande aktivitet.
SE7906037L (sv) Sterilisationssystem
US4931002A (en) Pyridoxal-5'-phosphate as an in vitro anticoagulant for whole blood
GB452000A (en) Improvements in or relating to dialysis
GB1407805A (en) Preservation of blood and maintenance of its 2,3-diphosphogly cerate content
KR790000537B1 (en) Method of instant icecream preparation
Trentz et al. Role of oxygen radicals in tourniquet-related ischemia-reperfusion injury of human patients
UA26116C2 (uk) Спосіб консервування еритроцитів

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee